Stepwise Access to Safe Plasma Proteins in Resource-Constrained Countries: Local Production & Pathways to Fractionation

Online Workshop organized by the Working Party for Global Blood Safety (GBS)

The program will feature presentations by experts from international organizations and associations (WHO, WFH, IPOPI, IPFA, PPTA) and suppliers of pathogen reduction technologies & plasma processing devices and equipment.

Scope and Purpose

The workshop will identify pragmatic technical options for stepwise access to safe plasma protein therapies in resource-constrained countries to support implementation of recent WHO guidance on “Increasing Supplies of Plasma-derived Medicinal Products in Low- and Middle-income Countries through Fractionation of Domestic Plasma” and “Centralization of Blood Donation Testing and Processing.”

WHO Guidances

https://www.who.int/publications/i/item/9789240021815
https://www.who.int/publications/i/item/9789240020825

Topics Covered

• Unmet clinical needs in safe plasma protein therapies for treatment of bleeding disorders and immunodeficiencies
• Robust quality and safety criteria of plasma for fractionation and plasma derived products, including coagulation factors and immunoglobulins
• Stepwise measures to avoid wasting recovered plasma and to increase availability of plasma for plasma protein manufacture
• Considerations to implement a contract/toll plasma fractionation program and to address technical and financial issues
• Cost considerations in plasma collection and fractionation 
• Interim alternatives to fractionation through local production by blood establishments of safe therapeutic plasma proteins: quarantine/retested plasma; pathogen-reduced plasma, cryo-poor plasma, and cryoprecipitate; pathogen-reduced mini-pool plasma products (cryoprecipitate, IgG, and other products)
• Single-use processing for local plasma protein purification and virus inactivation
• Technical solutions from the suppliers of single-use devices for local processing and virus inactivation of plasma, cryoprecipitate, cryoprecipitate poor plasma and immunoglobulins
• Role of suppliers in training of personnel and local implementation of technologies
• Regulatory considerations for validation of small/medium scale plasma processing

Click here for additional details.  Registration is free of charge.